Ex Vivo News and Research

RSS

Thyroxine may overcome mutated thyroid hormone receptor effects

Patients with a mutation in the thyroid hormone receptor α gene that affects both the thyroid hormone receptor α1 and α2 protein variants have similar characteristics to patients with mutations affecting only the α1 variant, report researchers.

3 Jul 2014

Research shows why breast cancer often metastasizes to lung

New research led by Alison Allan, PhD, a scientist at Western University and the Lawson Health Research Institute, shows why breast cancer often spreads or metastasizes to the lung.

25 Apr 2014

ATHENA develops surrogate organ system for toxicity testing

Creating surrogate human organs, coupled with insights from highly sensitive mass spectrometry technologies, a new project is on the brink of revolutionizing the way we screen new drugs and toxic agents.

29 Mar 2014

Researchers find good bacteria that protect women from HIV infection

Researchers at the University of Texas Medical Branch at Galveston by growing vaginal skin cells outside the body and studying the way they interact with "good and bad" bacteria, think they may be able to better identify the good bacteria that protect women from HIV infection and other sexually transmitted infections.

28 Mar 2014

Adherent stromal cells derived from human placenta improve tendon healing, shows study

According to Dr. Scott Rodeo of New York's Hospital for Special Surgery (HSS), although the findings of a recent study should be considered preliminary, adherent stromal cells derived from human placenta appear promising as a readily available cell source to aid tendon healing and regeneration.

17 Mar 2014

Novel HIV prevention products for women demonstrate safety in clinical studies

Two early clinical studies of novel HIV prevention products for women - the first combination antiretroviral (ARV) vaginal ring and a vaginal film - show the products to be safe and open the door to product improvements that could expand options for women-initiated prevention tools. The results of both studies were presented today at the 21st Conference on Retroviruses and Opportunistic Infections.

5 Mar 2014

Research sheds light on pathological mechanisms that trigger psoriasis lesions

Streptococcal antigens (Streptococcus pyogenes) might be directly involved in the pathological mechanisms that result in the appearance of psoriasis lesions.

21 Feb 2014

Spontaneous tumorigenic transformation of human MSCs can occur during cell culture expansion

Researchers at Erasmus University Medical Center Rotterdam, The Netherlands, led by Dr. Qiuwei Pan and Dr. Luc van der Laan, have discovered that spontaneous tumorigenic transformation of human mesenchymal stem/stromal cells (MSCs) can occur during cell culture expansion, although the frequency is relatively low and often only observed after extensive passage in culture.

30 Jan 2014

Groundbreaking UVA research receives $3.3M NIH grant to increase lungs for transplantation

Groundbreaking research at the University of Virginia School of Medicine that aims to dramatically increase the number of lungs that can be used for transplant has received a $3.3 million grant from the National Institutes of Health.

13 Dec 2013

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD), at the 55th Annual Meeting of the American Society of Hematology (ASH) held December 7 - 10, 2013 in New Orleans.

10 Dec 2013

Research: Human neural stem cells could improve blood flow in critical limb ischemia

New research has shown human neural stem cells could improve blood flow in critical limb ischemia through the growth of new vessels. Critical limb ischemia is a disease that severely obstructs arteries and reduces the blood flow to legs and feet. CLI remains an unmet clinical problem and with an ageing population and the rise in type II diabetes, the incidence of CLI is expected to increase.

27 Nov 2013

New microbicide gel formulation shows promise for safe vaginal and rectal administration to prevent HIV

Researchers developed a first-of-its-kind microbicide gel formulation that shows promise for safe vaginal and rectal administration to prevent the sexual transmission of human immunodeficiency virus (HIV).

15 Nov 2013

Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Cancer can be treated by a number of different ways depending on the location, grade and stage of tumour. A patient's age, medical history and lifestyle will also be taken into consideration and a combination of treatments will also be adopted to provide maximum effect.

14 Nov 2013

Viropharma announces financial results for third quarter 2013

ViroPharma Incorporated reported today its financial results for the third quarter ended September 30, 2013. Net sales were $113 million for the third quarter ended September 30, 2013, as compared to $91 million in the same three months of 2012.

31 Oct 2013

New DNA vaccine effective against plaques in mouse model of Alzheimer's disease

Amyloid-beta (Aβ) active immunization in Alzheimer's disease can increase the rate of Aβ clearance, and delay cognitive dysfunction, but it is easy to induce meningoencephalitis, which may be related to activation of Th1 lymphocytes.

30 Oct 2013

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of defactinib (VS-6063) in combination with paclitaxel in patients with ovarian cancer that were presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

21 Oct 2013

NCI Re-Ups Biomarker Strategies’ SBIR Award For Melanoma Cdx

BioMarker Strategies received a $1.5 million SBIR award to develop a pathway-based companion diagnostic test to facilitate the selection of optimal therapy for patients with melanoma. This award was preceded by an NCI award of $200,000 almost two years ago in September 2011.

25 Sep 2013

Scientists develop novel, rapid way to test artemisinin-resistant malaria

For the first time, scientists have developed a novel and rapid way to test whether the most common and lethal form of malaria is resistant to potent artemisinin drugs.

12 Sep 2013

Wake Forest Baptist conducts $24 million project to accelerate development of new therapies

Whether it's the Ebola virus or Sarin and Ricin, a key to responding to chemical or biological attacks is having effective antidotes at the ready. To accelerate the development of new therapies, Wake Forest Baptist Medical Center's Institute for Regenerative Medicine is leading a unique $24 million federally funded project to develop a "body on a chip" that will be used to develop these countermeasures.